Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26351952 | 0.89 | ALDH1A1 (0.57) | MAPTALDH1A1LMNAKCNH2POLB | |
| SCHEMBL5203786 | 0.85 | ALDH1A1 (0.60) | MAPTALDH1A1LMNAKCNH2MAPK1 | |
| SCHEMBL4460142 | 0.84 | MAPT (0.59) | MAPTALDH1A1LMNAKCNH2BACE1 | |
| SCHEMBL1247295 | 0.84 | MAPT (0.59) | MAPTALDH1A1LMNAKCNH2MAPK1 | |
| SCHEMBL2969622 | 0.83 | ALDH1A1 (0.54) | MAPTALDH1A1LMNAKCNH2NR1H2 | |
| SCHEMBL7352143 | 0.83 | KMT2A (0.52) | MAPTALDH1A1LMNANR1H2POLB | |
| SCHEMBL29745194 | 0.83 | MAPT (0.58) | MAPTALDH1A1LMNAKCNH2NR1H2 | |
| SCHEMBL3854881 | 0.83 | MAPT (0.58) | MAPTALDH1A1LMNAKCNH2MAPK1 | |
| SCHEMBL4178856 | 0.83 | MAPT (0.58) | MAPTALDH1A1LMNAKCNH2NR1H2 | |
| SCHEMBL29502254 | 0.82 | SMARCA2 (0.48) | MAPTALDH1A1LMNANR1H2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-04-10 | — | — | US | disclosed |
| US-12150995-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12097261-B2 | CDK2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4334307-A1 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022236058-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | MAPT 3470/4885ALDH1A1 4348/4885LMNA 2896/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MAPT 2971/4885ALDH1A1 2904/4885LMNA 4560/4885 |
| US-20250121073-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885ALDH1A1 2776/4885LMNA 1656/4885 |
| US-12150995-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885ALDH1A1 2776/4885LMNA 1656/4885 |
| US-12097261-B2 | CDK2 degraders and uses thereof | CDK2, CDK20, CDK1 | MAPT 2735/4885ALDH1A1 3701/4885LMNA 1186/4885 |
| US-20250114461-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MAPT 2735/4885ALDH1A1 3701/4885LMNA 1186/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | MAPT 1491/4885ALDH1A1 3918/4885LMNA 1420/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MAPT 2735/4885ALDH1A1 3701/4885LMNA 1186/4885 |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | MAPT 2735/4885ALDH1A1 3701/4885LMNA 1186/4885 |
| US-20230101353-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAPT 2459/4885ALDH1A1 2776/4885LMNA 1656/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | MAPT 2971/4885ALDH1A1 2904/4885LMNA 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.